Therapeutic Plasma Exchange in Septic Shock: A Pilot Study
Key facts
- Who runs it
- University of Manitoba
- Where
- Canada11 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 80 people, planned
- Started
- 1 Jun 2023
- Expected to end
- Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Therapeutic Plasma Exchange
- Record updated
- 17 August 2025
Who can take part
- Age
- 16 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Other criteria
- Eligible patients must be admitted to an ICU and must meet all of the following inclusion criteria:
- ≥ 16 years of age
- Refractory hypotension documented within 48 hours prior to enrollment requiring the institution and ongoing use of vasopressor agents (phenylephrine, norepinephrine, vasopressin, epinephrine, midodrine or dopamine >5 mcg/kg/min) at enrollment. Refractory hypotension is defined as a systolic blood pressure (SBP) less than 90 mmHg, or SBP less than 30 mmHg below baseline, or a mean arterial blood pressure less than 65 mmHg, despite adequate fluid resuscitation
- Capacity to initiate plasma exchange with 48 hours of vasopressor initiation
- At least 1 other new organ dysfunction (in addition to refractory hypotension), defined by the following at the time of enrollment:; Creatinine ≥1.5x the known baseline creatinine within 7 days, or ≥ 26.5 µmol/l increase in 48 hours,; Need for invasive mechanical ventilation or a P/F ratio <250; Platelets <100 x109/L, or a drop of 50 x109/L in the 3 days prior to enrollment; Arterial pH < 7.30 or base deficit > 5 mmol/L in association with a lactate >/= to 3.0 mmol/L
- Known or suspected infection; 2.4.3 Exclusion criteria; We will exclude patients who have any one of the following criteria at the time of enrollment:
- Consent declined (refusal from patient, SDM, or physician)
- Clinically apparent alternate causes for shock (cardiogenic, hemorrhagic, obstructive, neurogenic or anaphylactic)
- Terminal illness with a life expectancy of less than 3 months
- Are pregnant
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The investigators propose to conduct a multi-center randomized pilot feasibility trial comparing therapeutic plasma exchange to standard of care in patients diagnosed with septic shock.
The 2 groups in the trial
- Treatment ArmTreatment being tested
Participants randomized to the Treatment Arm will received 1.0 plasma exchanges daily until discontinuation of vasopressors, death or to a maximum of 5 daily treatments. Solvent detergent plasma (SDP) or frozen plasma (FP) depending on availability will be used as the replacement fluid.
Treatment: Therapeutic Plasma Exchange
- Standard of Care ArmNo study treatment, for comparison
Participants randomized to the Control Arm will receive standard of care for the treatment of septic shock in accordance with local practice and informed by national and international guidelines.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 17 August 2025